As the world grapples with the complex challenges posed by various forms of cancer, there is a pressing need for personalized approaches to treatment. Thanks to AI, clinicians can now leverage a wealth of data that allows for tailored therapies that are optimized for individual patients’ genetic and phenotypic profiles. The potential of AI to transform oncology arises from its ability to analyze vast datasets swiftly, uncovering patterns that would be nearly impossible for human analysts to detect within a reasonable time frame.

One of the foremost applications of AI in precision oncology lies in the realm of diagnostic accuracy. The ability to detect and classify tumors at their earliest stages not only enhances the chances for successful treatment but also minimizes the risk of overtreatment. AI algorithms, fueled by machine learning, have become adept at interpreting complex medical images, such as histopathological slides and radiological scans, achieving results that consistently outperform traditional diagnostic methods. This technology serves as a vital ally for pathologists and radiologists alike, streamlining the diagnostic process and allowing for a focused clinical approach.

A further examination of AI’s contributions to precision oncology reveals its role in predicting patient outcomes. By analyzing clinical and genomic data, machine learning models can forecast how individual patients are likely to respond to specific treatments. This predictive power enables oncologists to make informed decisions about therapeutic strategies, reducing the trial-and-error approach that has historically characterized cancer treatment. As predictive analytics become more sophisticated, the hope is that they will lead to more favorable prognoses and fewer adverse effects.

The integration of AI in clinical trials is another notable advancement in precision oncology. Trials often suffer from inefficiencies, such as lengthy recruitment processes and difficulties in patient retention. However, AI-driven algorithms can enhance patient recruitment by identifying suitable candidates more efficiently based on specific eligibility criteria gathered from a vast database of patient records. Moreover, AI can monitor real-time data to provide insights that enhance patient adherence to treatment protocols, ultimately improving overall trial outcomes.

Moreover, Goda and Abdel-Aziz emphasize the transformative potential of AI in drug discovery and development. The traditional drug development paradigm is notoriously expensive and time-consuming. By leveraging AI, researchers are finding ways to accelerate the identification of novel drug candidates and their potential interactions with biological targets. By streamlining this process, the time from laboratory bench to patient bedside could drastically shorten, ushering in a new era of treatment possibilities for hard-to-treat cancers.

Despite these revolutionary advances, there are substantial ethical and regulatory challenges that accompany the integration of AI in oncology. The pervasive use of AI necessitates that clinicians and researchers confront important questions regarding patient data privacy, algorithmic bias, and the validation of AI-generated findings. Maintaining ethical standards is crucial to safeguarding patient trust and ensuring equitable access to these innovative tools, as disparities in technology access could exacerbate existing inequalities in healthcare.

Moreover, the authors address the ongoing discussion surrounding the interpretability of AI systems. The ‘black box’ nature of many machine learning models raises concerns about how decisions are made, potentially impacting clinical acceptance. Efforts are underway to develop AI solutions that not only deliver results but also elucidate the reasoning behind predictions. This transparency is essential for fostering clinician confidence in AI recommendations and ensuring that patients receive care that is not only effective but also comprehensible and justifiable.

In conclusion, the synthesis of AI in precision oncology heralds a profound shift in cancer treatment paradigms. As research progresses, the integration of cutting-edge AI technologies heralds a future in which oncology is not only data-rich but also tailored to the unique genetic blueprints of individual patients. This convergence of technology and biology may result in a new frontier for cancer care, ultimately improving outcomes for patients across diverse demographics.

It is essential to remain optimistic about the pathways ahead. As further studies build on the foundations laid by Goda and Abdel-Aziz, the promise of AI in precision oncology will likely blossom, leading to innovative treatments and improved patient outcomes. This research is emblematic of a broader scientific movement towards personalized medicine, designed to combat the complexities of cancer with targeted and effective interventions that meet patients where they are.

In summary, the remarkable intersection of artificial intelligence and precision oncology offers a glimpse into the future of cancer care, where treatment is not only comprehensive but tailored with unprecedented precision. As advancements continue to unfold, the medical community must embrace these technologies with both vigilance and enthusiasm, recognizing the profound impact they may have on the fabric of healthcare.

Subject of Research: The application of artificial intelligence in precision oncology.

Article Title: Exploiting artificial intelligence in precision oncology: an updated comprehensive review.

Article References:

Goda, R., Abdel-Aziz, A. Exploiting artificial intelligence in precision oncology: an updated comprehensive review.
J Transl Med 23, 1397 (2025). https://doi.org/10.1186/s12967-025-07308-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07308-2

Keywords: Precision oncology, artificial intelligence, machine learning, cancer treatment, diagnostic accuracy, predictive analytics, drug discovery, ethical challenges, clinical trials.

Ardila, Vivares-Builes, and Pineda-Vélez delve into this intricate interplay, exploring the implications of incorporating AI in oncology. The evolution of disease management, especially in a nuanced field like oncology, necessitates a thorough understanding of how machines can complement human intuition and the emotional intelligence required to navigate patient care. As the researchers highlight, while AI systems can process vast datasets and rapidly identify patterns that might elude even the most skilled oncologists, the human element remains crucial in making the final treatment decisions.

The promise of AI in oncology is evident, particularly in diagnostic processes. Algorithms trained on immense volumes of patient data can assist in identifying cancerous lesions on imaging studies with remarkable accuracy. However, the authors urge caution—understanding the limitations of these systems and ensuring that their deployment doesn’t overshadow the invaluable human components. This includes compassion, patient engagement, and the ability to contextualize clinical findings within individual patient narratives.

One of the central discussions in the article revolves around real-world implementation. How do we effectively integrate AI tools into existing healthcare frameworks? The authors ask critical questions about training, necessary infrastructure, and the potential resistance from medical professionals who may feel displaced by advanced technologies. This trepidation poses a significant barrier to implementation, necessitating comprehensive strategies that highlight the synergistic potential of human-AI collaboration in improving patient care.

Another critical point raised involves the need for patient-centric evidence. Should AI-generated recommendations be considered definitive, or do they require human discretion and contextual awareness? The authors assert that while AI can generate insights, the final treatment plans should incorporate the preferences and values of patients. This shift toward a more patient-driven approach is especially relevant as healthcare becomes increasingly focused on individual patient experiences and outcomes.

Moreover, the ethical implications of using AI in oncology are multifaceted. What data informs AI systems, and can inherent biases within those datasets influence outcomes? As the authors explore, an ethical framework is vital to ensure that AI applications do not inadvertently perpetuate existing disparities in healthcare access and treatment. The importance of transparency in AI algorithms is paramount; patients and clinicians alike must understand how decisions are made and whose data is influencing care recommendations.

As conversations around AI and oncology progress, legislative support becomes crucial. Regulatory bodies must establish guidelines that ensure the safe and effective use of AI technologies in clinical practice. The authors posit that collaboration among technologists, health policy experts, and oncologists is essential for creating a robust regulatory framework that protects patients while promoting innovation.

The authors further emphasize the educational imperative that accompanies the introduction of AI in oncology. Physicians and healthcare practitioners need training not only in the technical aspects of AI applications but also in how to integrate these tools into their practices effectively. This education should include an understanding of the limitations of AI, fostering a mindset that values both data-driven insights and human judgment.

Engaging patients in the conversation about AI in healthcare is another critical component. The authors stress that patients must be part of the discussion regarding how AI tools may affect their diagnosis, treatment, and overall care experience. Creating a transparent dialogue can help build trust, alleviate concerns about the impersonal nature of technology, and foster a collaborative environment where patients feel empowered in their treatment journeys.

Additionally, the impact of AI is not only confined to diagnostics but also extends to treatment planning and outcome prediction. AI systems can analyze myriad variables—genetic data, treatment histories, and lifestyle factors—to offer predictions about how a patient might respond to specific therapies. While this can aid oncologists in tailoring treatment plans, the human touch remains vital, especially in discussions about the risks, benefits, and potential trade-offs of different treatment options.

As we look to the future, the researchers convey an optimistic yet cautious perspective. The amalgamation of AI and human reasoning holds the potential to revolutionize oncology, but its success depends on thoughtful implementation, ongoing research, and a commitment to ethical considerations. The journey ahead will require not only technological advancement but also a robust dialogue among all stakeholders in the healthcare ecosystem.

Ultimately, the integration of AI into oncology is not merely a technological challenge; it is a multidimensional human endeavor. By prioritizing collaboration, empathy, and ethics, the potential of AI can be harnessed to create a more effective, patient-centered approach to cancer care. As the authors poignantly suggest, the future of oncology lies not solely in algorithms or predictions but in a holistic strategy that embraces both human wisdom and artificial intelligence as co-partners in the quest for better patient outcomes.

The unfolding story of AI in oncology is just beginning. As more research emerges and real-world applications are developed, the intersection of technology, medicine, and patient care will continue to captivate researchers, clinicians, and patients alike. The dialogue initiated by Ardila, Vivares-Builes, and Pineda-Vélez is essential as we navigate this complex and rapidly evolving landscape, ensuring that the evolution of cancer care remains centered on the most important element: the patient.

Subject of Research: The integration of artificial intelligence with human reasoning in oncology, exploring implementation and patient-centric evidence.

Article Title: Integrating artificial intelligence with human reasoning in oncology: questions on real-world implementation and patient-centric evidence

Article References:

Ardila, C.M., Vivares-Builes, A.M. & Pineda-Vélez, E. Integrating artificial intelligence with human reasoning in oncology: questions on real-world implementation and patient-centric evidence.
Military Med Res 12, 75 (2025). https://doi.org/10.1186/s40779-025-00663-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40779-025-00663-7

Keywords: artificial intelligence, oncology, patient-centered care, ethics, implementation, collaboration, diagnostics, treatment planning

Oral squamous cell carcinoma is notoriously aggressive and known for its propensity to metastasize, leading to poor prognoses and limited treatment options for patients. The complexities involved in predicting the behavior of this malignancy have long hindered clinicians’ abilities to tailor effective therapies for individual patients. However, the research team led by X. Han has utilized advanced machine learning methodologies to analyze extensive datasets, enabling the identification of crucial patterns and factors that influence metastasis.

The study’s methodology involved the integration of diverse machine learning algorithms, each contributing uniquely to the overall model’s efficacy. By synthesizing insights from various approaches, the researchers aimed to create a robust and reliable predictive tool. From random forests to support vector machines, a comprehensive suite of analytical techniques was employed, allowing the team to leverage the strengths of each algorithm while minimizing individual weaknesses.

Through meticulous data collection, including clinical, genomic, and imaging information from patients diagnosed with OSCC, the team generated an extensive dataset that fueled their machine learning processes. This holistic approach not only provided depth to their analysis but also reinforced the model’s validity across different patient demographics and treatment regimens. The result was a predictive model that not only assessed the risk of metastasis but also proposed tailored treatment strategies based on individual patient profiles.

One of the standout features of the developed risk model is its ability to deliver real-time prognostic assessments. This feature could revolutionize clinical decision-making, allowing oncologists to provide personalized care plans while proactively addressing the challenges posed by metastasis. Early detection of high-risk patients through this model could lead to timely interventions, potentially improving survival rates in an area of medicine where delays can be perilous.

Moreover, the implications of this research extend beyond immediate patient care. By providing a framework for understanding the mechanisms underlying metastasis in OSCC, the model opens avenues for further research into therapeutic targets. This could lead to the development of new drugs aimed at combating the specific pathways identified as high-risk, setting the stage for more effective treatments in the future.

In addition to its clinical applications, the study emphasizes the role of interdisciplinary collaboration in advancing cancer research. The findings underscore the importance of combining expertise from various fields—including bioinformatics, machine learning, and clinical oncology—to address complex health issues in innovative ways. This collaborative approach not only enhances the quality of research but also fosters an environment conducive to breakthroughs that could save lives.

As the research team prepares for potential clinical trials based on their findings, the excitement within the scientific community is palpable. Medical professionals and researchers alike are eagerly anticipating the potential of this model to change the landscape of patient management in oral squamous cell carcinoma. The prospect of utilizing AI and machine learning in such a critical field highlights the relentless drive towards integrating technology with healthcare.

Furthermore, the study highlights the need for continuous refinement of machine learning models, underscoring that as more data becomes available, the algorithms can be fine-tuned to improve accuracy and predictive power. This iterative process is crucial, as it ensures that the model remains responsive to emerging trends in cancer treatment and patient outcomes.

Given the prevalence of oral squamous cell carcinoma in certain demographics, the potential for widespread impact is immense. As incidence rates continue to rise, particularly in populations with high tobacco and alcohol use, a predictive model offering superior risk assessment and management strategies could prove invaluable. The forthcoming clinical applications of this research could place it on the forefront of transformative cancer care.

Equally important is the ethical dimension of employing machine learning in healthcare. The researchers have meticulously considered the implications of their model to ensure transparency and fairness in its application. Efforts have been made to minimize biases that could skew results and adversely affect patient outcomes. This vigilance is paramount in maintaining trust in AI-driven healthcare solutions.

In conclusion, the research undertaken by Han and colleagues signifies a pivotal step forward in the fight against oral squamous cell carcinoma. By harnessing the power of machine learning, they have created a unique risk model that promises to enhance prognostic evaluations and clinical decision-making. The potential to improve patient outcomes in such a challenging cancer underscores the importance of innovation in medical research. As the scientific community eagerly awaits further developments, the integration of technology in cancer treatment continues to offer hope in the relentless battle against this disease.

The future of oncology is being shaped today, and with studies like this one, there is renewed optimism for better patient management strategies, customized treatment plans, and ultimately, improved survival rates for those affected by OSCC.

Subject of Research: Cancer metastasis risk model for oral squamous cell carcinoma

Article Title: Development of a cancer metastasis-associated risk model via multi-machine-learning algorithms for prognostic risk evaluation and clinical application in oral squamous cell carcinoma.

Article References:

Han, X., Sun, T., Dai, Y. et al. Development of a cancer metastasis-associated risk model via multi-machine-learning algorithms for prognostic risk evaluation and clinical application in oral squamous cell carcinoma.
J Transl Med 23, 1344 (2025). https://doi.org/10.1186/s12967-025-07336-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07336-y

Keywords: Oral squamous cell carcinoma, machine learning, risk model, metastasis, prognostic evaluation.

Colorectal cancer remains one of the leading causes of cancer-related morbidity worldwide. The aggressive chemotherapy regimens used to combat CRC, while effective, frequently induce a spectrum of toxicities that can severely compromise a patient’s ability to continue treatment. Chemotoxicity affects not only clinical outcomes but also the patient’s quality of life, often resulting in dose reductions, delays, or even discontinuation of therapy. Traditionally, oncologists rely on clinical judgment and general risk factors to anticipate such toxicities, but these methods lack precision and fail to account for the complex interplay between biology and socio-environmental factors.

The novel study harnessed data from 1,735 adult CRC patients, integrating electronic health records with detailed sociodemographic parameters, biological aging indicators, and geospatial deprivation indices. Biological aging was quantified using Levine Phenotypic Age—a method that reflects physiologic decline beyond chronological age by analyzing biomarkers of systemic aging. SDOH variables, such as the Area Deprivation Index (ADI) and employment status, provided critical context about patient environments and socioeconomic challenges, factors increasingly recognized as pivotal in health outcomes.

For model training and validation, the researchers employed six different supervised machine learning algorithms, including Support Vector Machines (SVM) and the advanced XGBoost model. These algorithms were trained on 80% of the patient data, while the remaining 20% was reserved for rigorous testing. Performance metrics focused on accuracy, area under the curve (AUC), and F1-score, ensuring that the models not only identified toxicities effectively but also balanced sensitivity and specificity.

Remarkably, both the SVM and XGBoost models demonstrated exceptional accuracy across all datasets, with the SVM model achieving an AUC of 0.988 in predicting overall chemotoxicity within the training cohort. This high performance underscores the potential of machine learning to discern subtle patterns in multifactorial data that human analysis might overlook. It also marks a significant step toward deploying AI-driven tools in clinical oncology decision-making frameworks.

Among the most influential predictors of overall and gastrointestinal (GI) chemotoxicities were elevated levels of biological aging as measured by Levine Phenotypic Age and increased systemic inflammation, signified by markers such as C-reactive protein. These findings suggest that patients exhibiting accelerated biological aging or chronic inflammatory states are at heightened risk of adverse chemotherapy reactions, indicating a compelling biological basis for toxicity susceptibility.

Beyond biological aging and inflammation, social determinants played a crucial role. Patients residing in disadvantaged neighborhoods with higher ADI scores and those who were unemployed faced greater risks of chemotoxic effects. The study’s integration of geospatial deprivation metrics offers a novel lens through which clinicians can appreciate how extrinsic socioeconomic stressors translate into tangible treatment vulnerabilities, thus broadening the scope of predictive oncology beyond purely molecular parameters.

Interestingly, hematological toxicity presented an inverse pattern; it was associated with lower inflammatory markers but still linked to elevated biological aging and younger chronological age. This dichotomy implies fundamentally different mechanistic pathways underlie various toxicity phenotypes, emphasizing the necessity for tailored predictive models that accommodate these distinctions.

Racialized group identity emerged as an independent modifier of toxicity risk, with non-Hispanic Black patients disproportionately affected by overall and GI toxicities. This disparity remained significant even after adjusting for socioeconomic and biological factors, highlighting persistent systemic inequities that permeate cancer care outcomes. The authors advocate for incorporating race-conscious variables in predictive modeling to ensure equitable and effective clinical interventions.

Lifestyle factors and body mass index (BMI) further modulated toxicity risks, reflecting the complex interplay between individual behaviors, physiologic status, and treatment tolerance. These insights may inform integrative treatment approaches that encompass not only pharmacologic interventions but also supportive measures addressing diet, exercise, and stress management.

Critically, the study offers a template for embedding multidimensional data—encompassing molecular, clinical, and social parameters—into AI-driven predictive tools with tangible clinical utility. Such models can empower oncologists to identify at-risk individuals proactively and implement preemptive strategies, such as the use of anti-inflammatory agents or therapies targeting biological aging pathways, to abrogate toxicity and optimize treatment courses.

Looking forward, these findings encourage a paradigm shift toward precision oncology that transcends tumor genomics and includes patient-centered variables influencing treatment response. By tailoring chemotherapy regimens based on individualized risk profiles, healthcare providers may improve survival outcomes while mitigating the harsh adverse effects that often accompany aggressive cancer therapies.

This research also illustrates the burgeoning role of machine learning in unpacking complex biomedical challenges. As vast amounts of clinical and sociodemographic data become increasingly accessible, AI tools promise to transform raw information into actionable insights, driving innovations in cancer care and beyond.

Crucially, the successful incorporation of SDOH and biological aging into predictive analytics exemplifies the necessity of holistic patient assessment. Oncology’s future arguably resides in multidisciplinary models that address both the biological tumor and the socio-environmental context in which treatment occurs, thereby closing the gap on health disparities.

The deployment of such predictive models in routine clinical settings, however, requires careful validation in diverse patient populations and robust infrastructures to integrate AI outputs with electronic health systems. Ethical considerations—particularly addressing biases within datasets and ensuring equitable access—must guide the translational pathway toward real-world implementation.

In essence, this study represents a monumental stride toward AI-powered personalized medicine in colorectal cancer, one that acknowledges the complex, multifaceted nature of chemotoxicity risk. As translational research continues, the prospect of mitigating chemotherapy side effects through smarter risk stratification and targeted intervention holds promise not just for improving patient experiences but also for enhancing overall cancer control.

By synergizing cutting-edge computational techniques with comprehensive patient profiling, the future of oncology care is poised to become more predictive, precise, and equitable—transforming the daunting challenges of chemotoxicity into manageable aspects of cancer therapy.

Subject of Research: Artificial intelligence and machine learning models predicting chemotoxicity in colorectal cancer by integrating racialized group, social determinants of health, and biological aging metrics.

Article Title: AI-driven chemotoxicity prediction in colorectal cancer: impact of race, SDOH, and biological aging

Article References:
Han, C., Burd, C., Plascak, J. et al. AI-driven chemotoxicity prediction in colorectal cancer: impact of race, SDOH, and biological aging. BMC Cancer 25, 1513 (2025). https://doi.org/10.1186/s12885-025-14831-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14831-4

Pancreatic cancer remains notorious for its dismal prognosis, largely due to its aggressive nature and tendency for early metastasis, particularly to the liver. The early detection of liver metastasis is paramount, as it directly influences treatment strategies and survival rates. However, traditional predictive methods often fall short in accuracy, underscoring the urgent need for more sophisticated, data-driven tools that could provide personalized prognosis.

Researchers conducted an expansive retrospective study involving 407 patients who underwent PDAC surgery at the First Affiliated Hospital of Soochow University over nearly a decade, from 2015 to 2023. This large dataset formed the foundation upon which advanced machine learning techniques were applied in an effort to extract predictive patterns invisible to the human eye.

To build their predictive engine, the research team employed seven diverse machine learning algorithms, each bringing unique strengths in pattern recognition and data fitting. The dataset was judiciously split, using 284 patients for developing and meticulously tuning the algorithms, while 123 patients formed an internal validation cohort to assess the model’s initial reliability.

Critical to the model’s real-world applicability was external validation. The team sourced data from 131 PDAC patients treated at the Affiliated Hospital of Nantong University, testing the model across independent populations. This crucial step was instrumental in demonstrating the model’s generalizability, a non-negotiable criterion in clinical AI tools destined for diverse healthcare settings.

An impressive 36.1% of the patients developed early liver metastasis within one year post-surgery, highlighting the clinical urgency underlying the study. Among an extensive set of 22 disease characteristics, sophisticated feature selection distilled the dataset to nine pivotal predictors. These parameters encapsulate complex disease dynamics and patient-specific factors, allowing the model to grasp nuances crucial for precise predictions.

Among the machine learning approaches, the XGBoost algorithm stood out, achieving unparalleled performance metrics. Notably, it recorded an Area Under the Receiver Operating Characteristic Curve (AUC) of 0.901, a statistical testament to its ability to discriminate between patients who would or would not develop early liver metastasis. Additional metrics such as accuracy (0.846), sensitivity (0.756), specificity (0.897), and F1 score (0.782) underscore the model’s balanced and robust predictive power.

Calibration, often overlooked in predictive models, was rigorously assessed through the Brier score, which stood at an impressive 0.12—indicative of high reliability in probability estimates provided by the model. In other words, the predicted risks align closely with actual clinical outcomes, an essential feature for any prognostic tool.

The interpretability of machine learning models, frequently criticized as “black boxes,” was addressed by integrating Shapley additive explanations (SHAP). SHAP methodology demystifies the algorithm’s decision-making process, attributing weights to individual features, thus enabling clinicians to understand which factors most significantly influence predictions. This transparency bolsters clinician confidence and supports nuanced treatment planning.

Both internal and external validations substantiated the model’s consistency and robustness, demonstrated through conventional ROC curves as well as calibration and decision curve analyses. Clinical impact curves further illustrated the tangible benefits of model adoption, projecting enhanced decision-making pathways and patient outcomes in routine oncology practice.

Beyond technical sophistication, the research team has translated their AI model into an accessible application platform. This user-friendly tool equips clinicians with dynamic, real-time predictive insights, promoting tailored postoperative surveillance and therapeutic strategies, thereby potentially transforming PDAC management paradigms.

The implications of this research extend beyond immediate clinical utility. It represents a pivotal step towards personalized oncology, where predictive analytics can preempt clinical deterioration, optimize resource allocation, and ultimately contribute to extending survival and quality of life in patients grappling with pancreatic cancer.

As pancreatic cancer incidence shows upward trends worldwide, innovations like this machine learning model reinforce the critical synergy between computational intelligence and clinical acumen. Future research will likely focus on integrating multi-omics data and real-world clinical factors to refine and expand these predictive capabilities.

This study not only exemplifies the promise of AI in oncology but also reflects meticulous methodological rigor, transparent interpretability, and a clear vision for clinical translation. It paves the way for integrating data-driven decision support tools as staples in the complex armamentarium against metastatic pancreatic cancer.

In sum, the intersection of machine learning and surgical oncology heralds a new era of precision medicine. Predictive models like the XGBoost application described here are poised to shift the clinical landscape, enabling proactive interventions that could substantially modify the dismal trajectory of PDAC with early liver metastasis.

The ongoing challenge will be embedding such innovations into routine clinical workflows, ensuring equitable access, and continuously validating model performance amidst evolving cancer care standards. Nonetheless, the horizon looks promising as data science increasingly illuminates pathways to better outcomes in one of medicine’s most formidable battles.

Subject of Research: Predicting early liver metastasis after pancreatic ductal adenocarcinoma surgery using interpretable machine learning models.

Article Title: An interpretable machine learning model for predicting early liver metastasis after pancreatic cancer surgery.

Article References:
Zhu, H., Zhou, Y., Shen, D. et al. An interpretable machine learning model for predicting early liver metastasis after pancreatic cancer surgery. BMC Cancer 25, 1117 (2025). https://doi.org/10.1186/s12885-025-14503-3

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14503-3